ArdelyxMEX:ARDX 69 Market Cap is MXN22,331 Mil as of Jul. 02, 2026. GuruFocus rates MEX:ARDX with a GF Score™ of 69/100 and a GF Value™ of MXN195.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,427 Biotechnology companies, Ardelyx ranks better than 82.76% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ardelyx's share price for the quarter that ended in Mar. 2026 was MXN128.8. Ardelyx's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 247 Mil. Therefore, Ardelyx's market cap for the quarter that ended in Mar. 2026 was MXN31,810 Mil.
Ardelyx's quarterly market cap
increased
from Sep. 2025 (MXN29,691 Mil) to Dec. 2025 (MXN29,860 Mil) and
increased
from Dec. 2025 (MXN29,860 Mil) to Mar. 2026 (MXN31,810 Mil).
Ardelyx's annual market cap
increased
from Dec. 2023 (MXN25,647 Mil) to Dec. 2024 (MXN26,182 Mil) and
increased
from Dec. 2024 (MXN26,182 Mil) to Dec. 2025 (MXN29,860 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ardelyx's Enterprise Value for Today is MXN21,809 Mil.
Ardelyx (MEX:ARDX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ardelyx Market Cap Related Terms
Ardelyx Market Cap Historical Data
* Premium members only.
The historical data trend for Ardelyx's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ARDX vs AVLN, INBX, JBIO: Market Cap Comparison
For the Biotechnology subindustry, Ardelyx's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's Market Cap distribution charts can be found below:
* The bar in red indicates where Ardelyx's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ardelyx's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (MEX:ARDX) has a Market Cap of MXN22,331 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #246 out of 1427 companies in the Biotechnology industry, placing it in the top 17.2%.
Is Ardelyx's Market Cap too high?
Ardelyx's current Market Cap is MXN22,331 Mil. Based on the distribution chart, Ardelyx ranks #246 out of 1427 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ardelyx has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Market Cap compare to AVLN and INBX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #246 out of 1427 companies for Market Cap. This places Ardelyx in the top 17% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ardelyx and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ardelyx's current Market Cap is MXN22,331 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (MEX:ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN195.32, compared to a current price of MXN99.00 — trading 49.3% below its estimated fair value. The current Market Cap is MXN22,331 Mil. Ardelyx's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ardelyx (MEX:ARDX), the current Market Cap is MXN22,331 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (MEX:ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of MXN99.00 is trading 49.3% below its estimated GF Value™ of MXN195.32.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for MEX:ARDX:
Market Cap: MXN22,331 Mil
GF Value™: MXN195.32 vs. price of MXN99.00 (49.3% below fair value)
No single metric tells the full story. See the MEX:ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
69GF Score
Get the complete analysis for MEX:ARDX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ARDX has been successfully added to your 
